<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pmj</journal-id><journal-title-group><journal-title xml:lang="ru">Тихоокеанский медицинский журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Pacific Medical Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1609-1175</issn><publisher><publisher-name>TGMU</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.34215/1609-1175-2026-2-52-55</article-id><article-id custom-type="elpub" pub-id-type="custom">pmj-3141</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCHES</subject></subj-group></article-categories><title-group><article-title>Результаты доклинической (in vivo) оценки эффективности и безопасности первого отечественного стент-ретривера «Граспер»</article-title><trans-title-group xml:lang="en"><trans-title>Preclinical (in vivo) efficacy and safety assessment of the Russian-made Grasper stent retriever</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6100-3625</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Грачев</surname><given-names>Н. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Grachev</surname><given-names>N. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Грачев Никита Игоревич – доцент института хирургии.</p><p>690002, Владивосток, пр-т Острякова, 2; тел: +7 (984) 150-97-70</p></bio><bio xml:lang="en"><p>Nikita I. Grachev - Associate Professor of the Institute of Surgery.</p><p>690002, Vladivostok, 2, Ostryakova ave.; tel: +7 (984) 150-97-70</p></bio><email xlink:type="simple">nik-vgmu@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Раповка</surname><given-names>В. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Rapovka</surname><given-names>V. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Владивосток</p></bio><bio xml:lang="en"><p>Vladivostok</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ковалев</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kovalyov</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Новосибирск</p></bio><bio xml:lang="en"><p>Novosibirsk</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кретов</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kretov</surname><given-names>E. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Новосибирск</p></bio><bio xml:lang="en"><p>Novosibirsk</p></bio><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Тихоокеанский государственный медицинский университет; Владивосток Приморская краевая клиническая больница № 1</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pacific State Medical University; Primorsk Regional Clinical Hospital No. 1</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Тихоокеанский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pacific State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Новосибирский областной клинический кардиологический диспансер</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk Regional Clinical Cardiological Dispensary</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Центральная клиническая больница</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Central Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>19</day><month>07</month><year>2026</year></pub-date><volume>0</volume><issue>2</issue><fpage>52</fpage><lpage>55</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Грачев Н.И., Раповка В.Г., Ковалев Е.А., Кретов Е.И., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Грачев Н.И., Раповка В.Г., Ковалев Е.А., Кретов Е.И.</copyright-holder><copyright-holder xml:lang="en">Grachev N.I., Rapovka V.G., Kovalyov E.A., Kretov E.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.tmj-vgmu.ru/jour/article/view/3141">https://www.tmj-vgmu.ru/jour/article/view/3141</self-uri><abstract><sec><title>Цель</title><p>Цель: оценить эффективность и профиль безопасности отечественного стент-ретривера «Граспер» в доклинической модели окклюзии крупного внутричерепного сосуда, а также определить влияние фенотипа тромба и «процедурной нагрузки» на результаты тромбэктомии.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Исследование выполнено in vivo на 14 свиньях (41 эпизод окклюзии). Использованы три морфотипа аутологичных тромбов (красный, смешанный, белый). Эффективность оценивали по адаптированной шкале TICI (aTICI); эффект первого прохода (ЭПП) определяли как достижение aTICI 2c-3 после первого прохода. Анализировали число проходов, время «пункция – реперфузия», частоту эмболизации в новые территории (ENT) и ангиографические признаки сосудистой травмы.</p></sec><sec><title>Результаты</title><p>Результаты. ЭПП (aTICI 2c-3) достигнут в 51,2% случаев; успешная финальная реперфузия (aTICI 2b-3) – в 100%, aTICI 2c-3 – в 92,7%. Перфорации, контрастная экстравазация и летальность отсутствовали; диссекции зарегистрированы в 4,9% и ассоциировались с ≥ 4 проходами. ENT отмечена в 24,4% случаев и чаще наблюдалась при ≥ 3 проходах (40,0 против 15,4%). Эффективность зависела от макротипа тромба: при красных тромбах ЭПП составил 71,4% (в среднем 1,79 прохода), при белых – 23,1% (3,31 прохода; p &lt; 0,05).</p></sec><sec><title>Заключение</title><p>Заключение. Стент-ретривер «Граспер» продемонстрировал высокий уровень реканализации при благоприятном профиле безопасности. Число проходов является ключевым медиатором процедурного вреда и эмболических осложнений. Фенотип тромба определяет вероятность достижения эффекта первого прохода и должен учитываться при выборе первичной стратегии тромбэктомии.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Objective</title><p>Objective: To evaluate the efficacy and safety profile of the Grasper stent retriever, manufactured in Russia, in a preclinical model of large intracranial vessel occlusion. Furthermore, to determine the impact of clot phenotype and procedural burden on thrombectomy outcomes.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The study was conducted in vivo on 14 pigs, resulting in 41 episodes of occlusion. Three morphotypes of autologous clots were tested, including red, mixed, and white. Reperfusion was assessed using an adapted TICI (aTICI) scale. First pass effect (FPE) was defined as achieving aTICI 2c-3 after the first pass. Number of passes, puncture-to-reperfusion time, embolization to new territories (ENT), and angiographic vessel injury were analyzed.</p></sec><sec><title>Results</title><p>Results. FPE (aTICI 2c-3) was achieved in 51.2% of cases. Final successful reperfusion (aTICI 2b-3) was obtained in 100%, with aTICI 2c-3 in 92.7%. No perforations, contrast extravasation, or mortality occurred; dissections (4.9%) were associated with ≥ 4 passes. ENT was observed in 24.4% and was more frequent with ≥ 3 passes (40.0 vs 15.4%). Outcomes were clot-dependent: FPE reached 71.4% for red clots (mean 1.79 passes) versus 23.1% for white clots (3.31 passes; p &lt; 0.05).</p></sec><sec><title>Conclusion</title><p>Conclusion. The Grasper stent retriever demonstrated high recanalization efficacy with a favorable safety profile. Procedural burden is a key mediator of embolic and vascular complications. The clot phenotype influences the first pass effect and thus should be considered when selecting an initial thrombectomy strategy.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>механическая тромбэктомия</kwd><kwd>эффект первого прохода</kwd><kwd>фенотип тромба</kwd><kwd>эмболизация</kwd><kwd>доклиническая модель</kwd></kwd-group><kwd-group xml:lang="en"><kwd>mechanical thrombectomy</kwd><kwd>first pass effect</kwd><kwd>clot phenotype</kwd><kwd>embolization</kwd><kwd>preclinical model</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">авторы заявляют о финансировании проведенного исследования из собственных средств</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Jang KM, Choi HH, Nam TK, Byun JS. Clinical outcomes of first-pass effect after mechanical thrombectomy for acute ischemic stroke: a systematic review and meta-analysis. Clin Neurol Neurosurg. 2021;211:107030. doi: 10.1016/j.clineuro.2021.107030</mixed-citation><mixed-citation xml:lang="en">Jang KM, Choi HH, Nam TK, Byun JS. Clinical outcomes of first-pass effect after mechanical thrombectomy for acute ischemic stroke: a systematic review and meta-analysis. Clin Neurol Neurosurg. 2021;211:107030. doi: 10.1016/j.clineuro.2021.107030</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Mueller-Kronast NH, Zaidat OO, Froehler MT, et al. Systematic evaluation of patients treated with neurothrombectomy devices for acute ischemic stroke: primary results of the STRATIS registry. Stroke. 2017;48(10):2760–2768. doi: 10.1161/sTROKEAHA.117.016456.</mixed-citation><mixed-citation xml:lang="en">Mueller-Kronast NH, Zaidat OO, Froehler MT, et al. Systematic evaluation of patients treated with neurothrombectomy devices for acute ischemic stroke: primary results of the STRATIS registry. Stroke. 2017;48(10):2760–2768. doi: 10.1161/sTROKEAHA.117.016456.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Zaidat OO, Castonguay AC, Linfante I, Gupta R, Martin CO, Holloway WE, et al. First pass effect: a new measure for stroke thrombectomy devices. Stroke. 2018;49(3):660–666. doi: 10.1161/STROKEAHA.117.020315.</mixed-citation><mixed-citation xml:lang="en">Zaidat OO, Castonguay AC, Linfante I, Gupta R, Martin CO, Holloway WE, et al. First pass effect: a new measure for stroke thrombectomy devices. Stroke. 2018;49(3):660–666. doi: 10.1161/STROKEAHA.117.020315.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Almekhlafi MA, Marquering HA, Majoie CB, Liebeskind DS. Thrombolysis in cerebral infarction scoring at the core lab. J Neurosonol Neuroimag. 2018;10(2):95–99. doi: 10.31728/jnn.2018.00031.</mixed-citation><mixed-citation xml:lang="en">Almekhlafi MA, Marquering HA, Majoie CB, Liebeskind DS. Thrombolysis in cerebral infarction scoring at the core lab. J Neurosonol Neuroimag. 2018;10(2):95–99. doi: 10.31728/jnn.2018.00031.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Memon MZ, Daniel DD, Chaudhry MR, Grewal M, Saini V, Lukas J, et al. Clinical impact of the first pass effect on clinical outcomes in patients with near or complete recanalization during mechanical thrombectomy for large vessel ischemic stroke. J Neuroimaging. 2021;31(4):743–750. doi: 10.1111/jon.12864</mixed-citation><mixed-citation xml:lang="en">Memon MZ, Daniel DD, Chaudhry MR, Grewal M, Saini V, Lukas J, et al. Clinical impact of the first pass effect on clinical outcomes in patients with near or complete recanalization during mechanical thrombectomy for large vessel ischemic stroke. J Neuroimaging. 2021;31(4):743–750. doi: 10.1111/jon.12864</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
